A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer / Kindler, H.l., Richards, D.a., Garbo, L.e., Garon, E.b., Stephenson JJ, J.r., Rocha Lima, C.m., Safran, H., Chan, D., Kocs, D.m., Galimi, F., Mcgreivy, J., Bray, S.l., Hei, Y., Feigal, E.g., Loh, E., Fuchs, C.s.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:11(2012), pp. 2834-2842. [10.1093/annonc/mds142]